Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

[Combination drug therapy in patients with BPH].

Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA.

Urologiia. 2018 Mar;(1):101-105. Russian.

PMID:
29634142
2.

[Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].

Vinarov AZ, Spivak LG, Mironov AV.

Urologiia. 2017 Sep;(4):120-128. Russian.

PMID:
28952704
3.

Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.

Traish A, Haider KS, Doros G, Haider A.

Horm Mol Biol Clin Investig. 2017 Jun 21;30(3). pii: /j/hmbci.2017.30.issue-3/hmbci-2017-0015/hmbci-2017-0015.xml. doi: 10.1515/hmbci-2017-0015.

PMID:
28632494
4.

Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, Puzzolo D, Valenti A, Pisani A, Adamo EB, Altavilla D, Squadrito F, Micali A.

Int J Mol Sci. 2016 Aug 11;17(8). pii: E1311. doi: 10.3390/ijms17081311. Review.

6.

Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

Fossler M, Zhu J, Roehrborn C, McAleese P, Manyak M.

Clin Drug Investig. 2016 Sep;36(9):763-767. doi: 10.1007/s40261-016-0419-6.

PMID:
27356530
7.

Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.

Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Palacios JM, Vasylyev A, Manyak MJ.

World J Urol. 2017 Mar;35(3):421-427. doi: 10.1007/s00345-016-1884-5. Epub 2016 Jun 22.

8.

Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers.

Li H, Yang J, Zhao H, Fossler MJ, Wang C.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):427-33. doi: 10.1002/cpdd.197. Epub 2015 Jul 20.

PMID:
27137714
9.

Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.

Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, García-Rojo D, Brenes-Bermúdez FJ, Cózar-Olmo JM, Baena-González V, Manasanch J.

Int Urol Nephrol. 2016 May;48(5):645-56. doi: 10.1007/s11255-015-1206-7. Epub 2016 Jan 25.

10.

The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis.

Skeldon SC, Kozhimannil KB, Majumdar SR, Law MR.

J Gen Intern Med. 2015 Apr;30(4):514-20. doi: 10.1007/s11606-014-3063-y. Epub 2014 Oct 23.

Supplemental Content

Loading ...
Support Center